These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36028470)

  • 1. Biologics for pediatric moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis.
    Huang IH; Yu CL; Tai CC; Tu YK; Chi CC
    J Dtsch Dermatol Ges; 2022 Sep; 20(9):1201-1209. PubMed ID: 36028470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.
    Tada Y; Watanabe R; Noma H; Kanai Y; Nomura T; Kaneko K
    J Dermatol Sci; 2020 Jul; 99(1):53-61. PubMed ID: 32600737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
    Huang IH; Wu PC; Chiu HY; Huang YH
    Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
    Sawyer LM; Cornic L; Levin LÅ; Gibbons C; Møller AH; Jemec GB
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):355-366. PubMed ID: 30289198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis.
    Armstrong AW; Puig L; Joshi A; Skup M; Williams D; Li J; Betts KA; Augustin M
    JAMA Dermatol; 2020 Mar; 156(3):258-269. PubMed ID: 32022825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis.
    Warren RB; Gooderham M; Burge R; Zhu B; Amato D; Liu KH; Shrom D; Guo J; Brnabic A; Blauvelt A
    J Am Acad Dermatol; 2020 May; 82(5):1138-1149. PubMed ID: 31884091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness of abatacept, apremilast, secukinumab and ustekinumab treatment of psoriatic arthritis: a systematic review and network meta-analysis.
    Kawalec P; Holko P; Moćko P; Pilc A
    Rheumatol Int; 2018 Feb; 38(2):189-201. PubMed ID: 29285605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis.
    Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Puig L; Augustin M
    Dermatol Ther (Heidelb); 2021 Jun; 11(3):885-905. PubMed ID: 33788177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
    J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
    Sawyer LM; Malottki K; Sabry-Grant C; Yasmeen N; Wright E; Sohrt A; Borg E; Warren RB
    PLoS One; 2019; 14(8):e0220868. PubMed ID: 31412060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis.
    Armstrong AW; Soliman AM; Betts KA; Wang Y; Gao Y; Stakias V; Puig L
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):167-184. PubMed ID: 34862951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials.
    Schmitt J; Zhang Z; Wozel G; Meurer M; Kirch W
    Br J Dermatol; 2008 Sep; 159(3):513-26. PubMed ID: 18627372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method.
    Mrowietz U; Warren RB; Leonardi CL; Saure D; Petto H; Hartz S; Dossenbach M; Reich K
    J Eur Acad Dermatol Venereol; 2021 May; 35(5):1161-1175. PubMed ID: 33480102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials].
    Zhang Z; Schmitt J; Wozel G; Kirch W
    Med Klin (Munich); 2009 Feb; 104(2):125-36. PubMed ID: 19242664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
    Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis.
    Armstrong A; Fahrbach K; Leonardi C; Augustin M; Neupane B; Kazmierska P; Betts M; Freitag A; Kiri S; Taieb V; Slim M; Gomez NN; Warren RB
    Dermatol Ther (Heidelb); 2022 Aug; 12(8):1777-1792. PubMed ID: 35798920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.